BioArctic (BIOA B) Panoramica del titolo
BioArctic AB (publ) sviluppa in Svezia farmaci biologici per pazienti con disturbi del sistema nervoso centrale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 6/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
BIOA B Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di BioArctic AB (publ)
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | SEK 323.00 |
| Massimo di 52 settimane | SEK 364.40 |
| Minimo di 52 settimane | SEK 206.40 |
| Beta | -0.67 |
| Variazione di 1 mese | -1.88% |
| Variazione a 3 mesi | -0.25% |
| Variazione di 1 anno | 49.95% |
| Variazione a 3 anni | 9.12% |
| Variazione a 5 anni | 128.11% |
| Variazione dall'IPO | 1,013.79% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 29
BIOA B: Alzheimer’s Outcomes And Aging Biology Partnerships Will Shape Balanced Outlook
Analysts have raised their BioArctic price target from SEK303.80 to SEK316.75, citing updated assumptions on revenue growth, profit margin, and a lower future P/E multiple that they view as more closely aligned with recent Street research on comparable aging-related therapeutics companies. Analyst Commentary Street research on aging related therapeutics is shaping how bullish analysts frame expectations for BioArctic.
Aggiornamento narrativa • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.Recent updates
Aggiornamento narrativa • Jul 29
BIOA B: Alzheimer’s Outcomes And Aging Biology Partnerships Will Shape Balanced Outlook
Analysts have raised their BioArctic price target from SEK303.80 to SEK316.75, citing updated assumptions on revenue growth, profit margin, and a lower future P/E multiple that they view as more closely aligned with recent Street research on comparable aging-related therapeutics companies. Analyst Commentary Street research on aging related therapeutics is shaping how bullish analysts frame expectations for BioArctic.Aggiornamento narrativa • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.
Aggiornamento narrativa • Jun 01
BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns
Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.Articolo di analisi • May 28
BioArctic's (STO:BIOA B) Soft Earnings Don't Show The Whole Picture
BioArctic AB (publ)'s ( STO:BIOA B ) stock was strong despite it releasing a soft earnings report last week. We think...Articolo di analisi • May 24
BioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their Estimates
As you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...Aggiornamento narrativa • May 18
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts kept their SEK 240.00 price target for BioArctic unchanged, with slightly lower discount rate and profit margin assumptions, and a higher future P/E multiple that reflects refined views on the stock's risk profile and earnings power. Analyst Commentary Recent research on BioArctic has centered on how changing assumptions around risk, profitability, and long term earnings power feed into valuation.Aggiornamento narrativa • Apr 22
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.Aggiornamento narrativa • Apr 08
BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook
The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.Aggiornamento narrativa • Mar 25
BIOA B: Future Earnings Will Depend On High China Access Risk
Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.Aggiornamento narrativa • Mar 10
BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside
Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.Aggiornamento narrativa • Feb 24
BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe Upside
Analysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.Aggiornamento narrativa • Feb 09
BIOA B: Future Earnings Will Depend On Risky China Insurance Access
Analysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.Aggiornamento narrativa • Jan 25
BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access
Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.Aggiornamento narrativa • Jan 09
BIOA B: Future Earnings Will Depend On Risky Alzheimer Access Rollout
Analysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.Aggiornamento narrativa • Dec 26
BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks
Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.Aggiornamento narrativa • Dec 12
BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market Approval
Analysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.Articolo di analisi • Nov 16
BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...Aggiornamento narrativa • Sep 17
Overhyped Valuations Will Falter Amid Healthcare Headwinds
Despite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.Aggiornamento narrativa • Sep 02
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.Articolo di analisi • Aug 14
Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%
OM:BIOA B 1 Year Share Price vs Fair Value Explore BioArctic's Fair Values from the Community and select yours Despite...Nuova narrativa • Jun 01
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.Articolo di analisi • May 29
BioArctic's (STO:BIOA B) Solid Profits Have Weak Fundamentals
BioArctic AB (publ)'s ( STO:BIOA B ) robust earnings report didn't manage to move the market for its stock. Our...Articolo di analisi • May 16
Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights BioArctic will host its Annual General Meeting on 22nd of May CEO Gunilla Osswald's total compensation...Articolo di analisi • Feb 19
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Articolo di analisi • Feb 18
Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
It's been a good week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, because the company has just released its...Articolo di analisi • Jan 31
Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Articolo di analisi • Nov 27
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Celebrations may be in order for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with the analysts delivering a...Articolo di analisi • Sep 01
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
A week ago, BioArctic AB (publ) ( STO:BIOA B ) came out with a strong set of quarterly numbers that could potentially...Articolo di analisi • Aug 15
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
The analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...Articolo di analisi • Apr 13
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
With a price-to-sales (or "P/S") ratio of 30.5x BioArctic AB (publ) ( STO:BIOA B ) may be sending very bearish signals...Rendimenti per gli azionisti
| BIOA B | SE Biotechs | SE Mercato | |
|---|---|---|---|
| 7D | 5.3% | 2.0% | 1.3% |
| 1Y | 50.0% | 26.2% | 10.4% |
Ritorno vs Industria: BIOA B ha superato il Swedish Biotechs che ha restituito 26.2 % nell'ultimo anno.
Rendimento vs Mercato: BIOA B ha superato il mercato Swedish che ha restituito 10.4 % nell'ultimo anno.
Volatilità dei prezzi
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Prezzo delle azioni stabile: BIOA B non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swedish.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di BIOA B è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2000 | 141 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) sviluppa in Svezia farmaci biologici per pazienti con disturbi del sistema nervoso centrale. L'azienda si occupa di ricerca e sviluppo di farmaci biologici innovativi, come gli anticorpi, che rispondono a esigenze mediche fortemente insoddisfatte. Le sue aree terapeutiche comprendono disturbi neurodegenerativi, come il morbo di Alzheimer, il morbo di Parkinson e altre malattie del sistema nervoso centrale.
BioArctic AB (publ) Riepilogo dei fondamenti
| BIOA B statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | SEK 28.66b |
| Utili (TTM) | SEK 213.24m |
| Ricavi(TTM) | SEK 1.15b |
134.4x
Rapporto P/E25.0x
Rapporto P/SBIOA B è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| BIOA B Conto economico (TTM) | |
|---|---|
| Ricavi | SEK 1.15b |
| Costo del fatturato | SEK 67.32m |
| Profitto lordo | SEK 1.08b |
| Altre spese | SEK 866.53m |
| Utili | SEK 213.24m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 26, 2026
| Utile per azione (EPS) | 2.40 |
| Margine lordo | 94.13% |
| Margine di profitto netto | 18.59% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato BIOA B nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.6%
Rendimento attuale del dividendo83%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/30 00:39 |
| Prezzo dell'azione a fine giornata | 2026/07/30 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
BioArctic AB (publ) è coperta da 5 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |